Identification

Name
Fluorometholone
Accession Number
DB00324  (APRD00980)
Type
Small Molecule
Groups
Approved
Description

A glucocorticoid employed, usually as eye drops, in the treatment of allergic and inflammatory conditions of the eye. It has also been used topically in the treatment of various skin disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p732)

Structure
Thumb
Synonyms
  • (1R,2S,8S,10S,11S,14R,15S,17S)-14-acetyl-1-fluoro-14,17-dihydroxy-2,8,15-trimethyltetracyclo[8.7.0.02,7.011,15]heptadeca-3,6-dien-5-one
  • 9-Fluoro-11beta,17-dihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione
  • Fluorometholon
  • Fluorométholone
  • Fluorometholone
  • Fluorometholonum
  • Fluorometolona
  • NSC 33001
  • Oxylone
External IDs
U 17323
Product Ingredients
IngredientUNIICASInChI Key
Fluorometholone Acetate9I50C3I3OK3801-06-7YRFXGQHBPBMFHW-SBTZIJSASA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
FlarexSuspension0.1 %OphthalmicNovartis1987-12-31Not applicableCanada
FlarexSuspension / drops1 mg/mLOphthalmicAlcon, Inc.1992-02-06Not applicableUs
FluorometholoneSolution / drops1 mg/mLOphthalmicPacific Pharma1997-10-31Not applicableUs
FMLSuspension / drops1 mg/mLOphthalmicAllergan1972-02-01Not applicableUs
FMLOintment1 mg/gOphthalmicAllergan1985-12-09Not applicableUs
FML 0.1%Solution / drops0.1 %OphthalmicAllergan1972-12-31Not applicableCanada
FML ForteSuspension / drops2.5 mg/mLOphthalmicAllergan1986-05-01Not applicableUs
FML Forte Sus 0.25%Suspension0.25 %OphthalmicAllergan1987-12-312016-04-06Canada
PMS-fluorometholoneSuspension0.1 %OphthalmicPharmascience Inc2001-07-162016-10-28Canada
Sandoz FluorometholoneSuspension0.1 %OphthalmicSandoz Canada Incorporated2012-07-24Not applicableCanada
International/Other Brands
Efflumidex (Allergan) / Fluaton (Allergan) / Flumetholon (Ferron) / Fluor-op (Novartis Ophthalmics) / Flurolon (Allergan) / FML Liquifilm (Allergan) / Foxone (Winston) / Fucin (Mey See) / Fuluson (Dae Wo) / Fumelon (Han Lim) / Humetoron (Kuk Je)
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
FML-neo Oph SusFluorometholone (0.1 %) + Neomycin sulfate (0.5 %)SuspensionOphthalmicAllergan1977-12-312011-08-04Canada
Categories
UNII
SV0CSG527L
CAS number
426-13-1
Weight
Average: 376.4617
Monoisotopic: 376.204987621
Chemical Formula
C22H29FO4
InChI Key
FAOZLTXFLGPHNG-KNAQIMQKSA-N
InChI
InChI=1S/C22H29FO4/c1-12-9-17-15-6-8-21(27,13(2)24)20(15,4)11-18(26)22(17,23)19(3)7-5-14(25)10-16(12)19/h5,7,10,12,15,17-18,26-27H,6,8-9,11H2,1-4H3/t12-,15-,17-,18-,19-,20-,21-,22-/m0/s1
IUPAC Name
(1R,2S,8S,10S,11S,14R,15S,17S)-14-acetyl-1-fluoro-14,17-dihydroxy-2,8,15-trimethyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadeca-3,6-dien-5-one
SMILES

Pharmacology

Indication

For the ophthalmic treatment of corticosteroid-responsive inflammation of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe.

Structured Indications
Pharmacodynamics

Corticosteroids such as fluorometholone inhibit the inflammatory response to a variety of inciting agents and probably delay or slow healing. They inhibit the edema, fibrin deposition, capillary dilation, leukocyte migration, capillary proliferation, fibroblast proliferation, deposition of collagen, and scar formation associated with inflammation.

Mechanism of action

There is no generally accepted explanation for the mechanism of action of ocular corticosteroids. However, corticosteroids are thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor, arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2. Their primary target is the cytosolic glucocorticoid receptor. After binding the receptor the newly formed receptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes.

TargetActionsOrganism
AGlucocorticoid receptor
agonist
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity

Side effects may include acute anterior uveitis and perforation of the globe. Keratitis, conjunctivitis, corneal ulcers, mydriasis, conjunctival hyperemia, loss of accommodation and ptosis have occasionally been reported following local use of corticosteroids. LD50 = 234 mg/kg (rats)

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe risk or severity of adverse effects can be increased when Fluorometholone is combined with 1,10-Phenanthroline.Experimental
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Fluorometholone.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Acemetacin is combined with Fluorometholone.Approved, Experimental, Investigational
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Fluorometholone.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Fluorometholone.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Alclofenac is combined with Fluorometholone.Approved, Withdrawn
AldesleukinFluorometholone may decrease the antineoplastic activities of Aldesleukin.Approved
AlmasilateThe bioavailability of Fluorometholone can be decreased when combined with Almasilate.Approved, Experimental
AlminoprofenThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Fluorometholone.Experimental
AloglutamolThe bioavailability of Fluorometholone can be decreased when combined with Aloglutamol.Experimental
AloxiprinThe risk or severity of adverse effects can be increased when Aloxiprin is combined with Fluorometholone.Experimental
AluminiumThe bioavailability of Fluorometholone can be decreased when combined with Aluminium.Approved
Aluminium acetoacetateThe bioavailability of Fluorometholone can be decreased when combined with Aluminium acetoacetate.Experimental
Aluminium glycinateThe bioavailability of Fluorometholone can be decreased when combined with Aluminium glycinate.Experimental
Aluminum hydroxideThe bioavailability of Fluorometholone can be decreased when combined with Aluminum hydroxide.Approved
AmbenoniumThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Ambenonium.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Fluorometholone.Approved
AmiodaroneThe metabolism of Fluorometholone can be decreased when combined with Amiodarone.Approved, Investigational
Amphotericin BFluorometholone may increase the hypokalemic activities of Amphotericin B.Approved, Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Fluorometholone.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Fluorometholone.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Fluorometholone.Approved
ApocyninThe risk or severity of adverse effects can be increased when Apocynin is combined with Fluorometholone.Investigational
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Fluorometholone.Approved, Investigational
AprepitantThe serum concentration of Fluorometholone can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be decreased when it is combined with Fluorometholone.Approved, Investigational
AtazanavirThe metabolism of Fluorometholone can be decreased when combined with Atazanavir.Approved, Investigational
AtomoxetineThe metabolism of Fluorometholone can be decreased when combined with Atomoxetine.Approved
Atracurium besylateAtracurium besylate may increase the adverse neuromuscular activities of Fluorometholone.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Fluorometholone.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Fluorometholone.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Fluorometholone.Approved, Investigational
BCG vaccineThe risk or severity of adverse effects can be increased when Fluorometholone is combined with BCG vaccine.Investigational
BendazacThe risk or severity of adverse effects can be increased when Bendazac is combined with Fluorometholone.Experimental
BendroflumethiazideFluorometholone may increase the hypokalemic activities of Bendroflumethiazide.Approved
BenorilateThe risk or severity of adverse effects can be increased when Benorilate is combined with Fluorometholone.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Fluorometholone.Withdrawn
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be decreased when used in combination with Fluorometholone.Approved
BenzydamineThe risk or severity of adverse effects can be increased when Benzydamine is combined with Fluorometholone.Approved
BevoniumThe risk or severity of adverse effects can be increased when Bevonium is combined with Fluorometholone.Experimental
Bismuth SubcitrateThe bioavailability of Fluorometholone can be decreased when combined with Bismuth Subcitrate.Approved
Bismuth subnitrateThe bioavailability of Fluorometholone can be decreased when combined with Bismuth subnitrate.Experimental
BoceprevirThe metabolism of Fluorometholone can be decreased when combined with Boceprevir.Approved, Withdrawn
BortezomibThe metabolism of Fluorometholone can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Fluorometholone can be decreased when it is combined with Bosentan.Approved, Investigational
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Fluorometholone.Approved
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Fluorometholone.Investigational
BufexamacThe risk or severity of adverse effects can be increased when Bufexamac is combined with Fluorometholone.Experimental
BumadizoneThe risk or severity of adverse effects can be increased when Bumadizone is combined with Fluorometholone.Experimental
BumetanideFluorometholone may increase the hypokalemic activities of Bumetanide.Approved
CalcitriolThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Fluorometholone.Approved, Nutraceutical
Calcium CarbonateThe bioavailability of Fluorometholone can be decreased when combined with Calcium Carbonate.Approved
Calcium silicateThe bioavailability of Fluorometholone can be decreased when combined with Calcium silicate.Experimental
Capromab pendetideFluorometholone may decrease effectiveness of Capromab pendetide as a diagnostic agent.Approved
CarbamazepineThe metabolism of Fluorometholone can be increased when combined with Carbamazepine.Approved, Investigational
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Fluorometholone.Approved, Vet Approved, Withdrawn
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Fluorometholone.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Celecoxib.Approved, Investigational
CeritinibThe serum concentration of Fluorometholone can be increased when it is combined with Ceritinib.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Fluorometholone.Approved, Vet Approved
ChlorothiazideFluorometholone may increase the hypokalemic activities of Chlorothiazide.Approved, Vet Approved
ChlorotrianiseneThe serum concentration of Fluorometholone can be increased when it is combined with Chlorotrianisene.Investigational, Withdrawn
ChlorthalidoneFluorometholone may increase the hypokalemic activities of Chlorthalidone.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Fluorometholone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Fluorometholone.Approved
CinoxacinThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Cinoxacin.Approved, Investigational, Withdrawn
ClarithromycinThe metabolism of Fluorometholone can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Fluorometholone can be decreased when combined with Clemastine.Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Fluorometholone.Approved
Clostridium tetani toxoid antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Fluorometholone is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved
ClotrimazoleThe metabolism of Fluorometholone can be decreased when combined with Clotrimazole.Approved, Vet Approved
CobicistatThe metabolism of Fluorometholone can be decreased when combined with Cobicistat.Approved
ColesevelamColesevelam can cause a decrease in the absorption of Fluorometholone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Fluorometholone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ConivaptanThe serum concentration of Fluorometholone can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated estrogensThe serum concentration of Fluorometholone can be increased when it is combined with Conjugated estrogens.Approved
Corticorelin ovine triflutateThe therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Fluorometholone.Approved
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Fluorometholone is combined with Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated).Approved
CoumaphosThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Coumaphos.Vet Approved
CrizotinibThe metabolism of Fluorometholone can be decreased when combined with Crizotinib.Approved
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Fluorometholone.Investigational
CyclopenthiazideFluorometholone may increase the hypokalemic activities of Cyclopenthiazide.Experimental
CyclosporineThe metabolism of Fluorometholone can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
D-LimoneneThe risk or severity of adverse effects can be increased when D-Limonene is combined with Fluorometholone.Investigational
DabrafenibThe serum concentration of Fluorometholone can be decreased when it is combined with Dabrafenib.Approved
DaidzeinThe serum concentration of Fluorometholone can be increased when it is combined with Daidzein.Experimental
DanazolFluorometholone may increase the fluid retaining activities of Danazol.Approved
DarunavirThe metabolism of Fluorometholone can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Fluorometholone can be increased when it is combined with Dasatinib.Approved, Investigational
DecamethoniumThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Decamethonium.Approved
DeferasiroxThe serum concentration of Fluorometholone can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Fluorometholone can be decreased when combined with Delavirdine.Approved
DemecariumThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Demecarium.Approved
dersalazineThe risk or severity of adverse effects can be increased when dersalazine is combined with Fluorometholone.Investigational
DichlorvosThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Dichlorvos.Vet Approved
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Fluorometholone.Approved, Vet Approved
DienestrolThe serum concentration of Fluorometholone can be increased when it is combined with Dienestrol.Approved, Investigational
DiethylstilbestrolThe serum concentration of Fluorometholone can be increased when it is combined with Diethylstilbestrol.Approved, Investigational
DifenpiramideThe risk or severity of adverse effects can be increased when Difenpiramide is combined with Fluorometholone.Experimental
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Fluorometholone.Approved
DihydroergotamineThe metabolism of Fluorometholone can be decreased when combined with Dihydroergotamine.Approved
DihydrotestosteroneFluorometholone may increase the fluid retaining activities of Dihydrotestosterone.Illicit
DiltiazemThe metabolism of Fluorometholone can be decreased when combined with Diltiazem.Approved
DistigmineThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Distigmine.Experimental
DonepezilThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Donepezil.Approved
DoxycyclineThe metabolism of Fluorometholone can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe metabolism of Fluorometholone can be decreased when combined with Dronedarone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Fluorometholone.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Fluorometholone.Investigational
E-6201The risk or severity of adverse effects can be increased when E-6201 is combined with Fluorometholone.Investigational
EchothiophateThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Echothiophate.Approved
EdrophoniumThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Edrophonium.Approved
EnoxacinThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Enoxacin.Approved, Investigational
EnzalutamideThe serum concentration of Fluorometholone can be decreased when it is combined with Enzalutamide.Approved
EpimestrolThe serum concentration of Fluorometholone can be increased when it is combined with Epimestrol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Fluorometholone.Approved
EquolThe serum concentration of Fluorometholone can be increased when it is combined with Equol.Investigational
ErythromycinThe metabolism of Fluorometholone can be decreased when combined with Erythromycin.Approved, Vet Approved
EstradiolThe serum concentration of Fluorometholone can be increased when it is combined with Estradiol.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Fluorometholone can be increased when it is combined with Estriol.Approved, Investigational, Vet Approved
Estrogens, esterifiedThe serum concentration of Fluorometholone can be increased when it is combined with Estrogens, esterified.Approved
EstroneThe serum concentration of Fluorometholone can be increased when it is combined with Estrone.Approved
Etacrynic acidFluorometholone may increase the hypokalemic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Fluorometholone.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Ethenzamide is combined with Fluorometholone.Experimental
Ethinyl EstradiolThe serum concentration of Fluorometholone can be increased when it is combined with Ethinyl Estradiol.Approved
EtodolacThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Fluorometholone.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Etoricoxib.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Fluorometholone.Approved, Investigational
exisulindThe risk or severity of adverse effects can be increased when exisulind is combined with Fluorometholone.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Felbinac is combined with Fluorometholone.Experimental
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Fluorometholone.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Fluorometholone.Approved
FenthionThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Fenthion.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Fentiazac is combined with Fluorometholone.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Feprazone is combined with Fluorometholone.Experimental
Ferulic acidThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Fluorometholone.Experimental
FleroxacinThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Fluorometholone.Approved, Withdrawn
FluconazoleThe metabolism of Fluorometholone can be decreased when combined with Fluconazole.Approved
FlumequineThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Flumequine.Withdrawn
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Fluorometholone.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Flunoxaprofen is combined with Fluorometholone.Experimental
FluoxymesteroneFluorometholone may increase the fluid retaining activities of Fluoxymesterone.Approved, Illicit
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Fluorometholone.Approved, Investigational
FluvoxamineThe metabolism of Fluorometholone can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Fluorometholone can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Fluorometholone can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Fluorometholone can be increased when combined with Fosphenytoin.Approved
FurosemideFluorometholone may increase the hypokalemic activities of Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Fluorometholone can be increased when it is combined with Fusidic Acid.Approved
G17DTThe risk or severity of adverse effects can be increased when Fluorometholone is combined with G17DT.Investigational
GalantamineThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Galantamine.Approved
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Gallamine Triethiodide.Approved
GarenoxacinThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Garenoxacin.Investigational
GatifloxacinThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Gatifloxacin.Approved, Investigational
GemifloxacinThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Gemifloxacin.Approved, Investigational
GenisteinThe serum concentration of Fluorometholone can be increased when it is combined with Genistein.Investigational
GI-5005The risk or severity of adverse effects can be increased when Fluorometholone is combined with GI-5005.Investigational
GLPG-0492Fluorometholone may increase the fluid retaining activities of GLPG-0492.Investigational
Glycerol PhenylbutyrateThe therapeutic efficacy of Glycerol Phenylbutyrate can be decreased when used in combination with Fluorometholone.Approved
GrepafloxacinThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Grepafloxacin.Investigational, Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Guacetisal is combined with Fluorometholone.Experimental
Hemoglobin crosfumarilThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Fluorometholone.Experimental
Hepatitis A VaccineThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Hepatitis A Vaccine.Approved
Hepatitis B Vaccine (Recombinant)The risk or severity of adverse effects can be increased when Fluorometholone is combined with Hepatitis B Vaccine (Recombinant).Approved, Withdrawn
HexestrolThe serum concentration of Fluorometholone can be increased when it is combined with Hexestrol.Withdrawn
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Fluorometholone.Investigational
Huperzine AThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Huperzine A.Investigational
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Fluorometholone.Approved, Investigational
HydrochlorothiazideFluorometholone may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideFluorometholone may increase the hypokalemic activities of Hydroflumethiazide.Approved, Investigational
HydrotalciteThe bioavailability of Fluorometholone can be decreased when combined with Hydrotalcite.Experimental, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Fluorometholone.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Fluorometholone.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Fluorometholone.Approved
ImatinibThe metabolism of Fluorometholone can be decreased when combined with Imatinib.Approved
Imidazole salicylateThe risk or severity of adverse effects can be increased when Imidazole salicylate is combined with Fluorometholone.Experimental
IndacaterolIndacaterol may increase the hypokalemic activities of Fluorometholone.Approved
IndapamideFluorometholone may increase the hypokalemic activities of Indapamide.Approved
IndinavirThe metabolism of Fluorometholone can be decreased when combined with Indinavir.Approved
IndobufenThe risk or severity of adverse effects can be increased when Indobufen is combined with Fluorometholone.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Fluorometholone.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Fluorometholone.Withdrawn
INGN 201The risk or severity of adverse effects can be increased when Fluorometholone is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Fluorometholone is combined with INGN 225.Investigational
IpidacrineThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Ipidacrine.Experimental
IsavuconazoniumThe metabolism of Fluorometholone can be decreased when combined with Isavuconazonium.Approved, Investigational
IsoflurophateThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Isoflurophate.Approved, Investigational, Withdrawn
IsoniazidThe serum concentration of Isoniazid can be decreased when it is combined with Fluorometholone.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Fluorometholone.Withdrawn
IsradipineThe metabolism of Fluorometholone can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Fluorometholone can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Fluorometholone can be increased when it is combined with Ivacaftor.Approved
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Fluorometholone.Experimental
KetoconazoleThe metabolism of Fluorometholone can be decreased when combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Fluorometholone.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Fluorometholone.Approved
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Fluorometholone.Approved, Investigational
LevofloxacinThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Levofloxacin.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Fluorometholone.Investigational
LonazolacThe risk or severity of adverse effects can be increased when Lonazolac is combined with Fluorometholone.Experimental
LopinavirThe metabolism of Fluorometholone can be decreased when combined with Lopinavir.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Fluorometholone.Approved, Investigational
LovastatinThe metabolism of Fluorometholone can be decreased when combined with Lovastatin.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Fluorometholone.Approved, Investigational
LuliconazoleThe serum concentration of Fluorometholone can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Fluorometholone can be increased when combined with Lumacaftor.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Lumiracoxib.Approved, Investigational
MagaldrateThe bioavailability of Fluorometholone can be decreased when combined with Magaldrate.Approved, Withdrawn
Magnesium HydroxideThe bioavailability of Fluorometholone can be decreased when combined with Magnesium Hydroxide.Approved
Magnesium oxideThe bioavailability of Fluorometholone can be decreased when combined with Magnesium oxide.Approved
Magnesium peroxideThe bioavailability of Fluorometholone can be decreased when combined with Magnesium peroxide.Experimental
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Fluorometholone.Approved
Magnesium silicateThe bioavailability of Fluorometholone can be decreased when combined with Magnesium silicate.Approved, Experimental
Magnesium TrisilicateThe bioavailability of Fluorometholone can be decreased when combined with Magnesium Trisilicate.Approved
MalathionThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Malathion.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Fluorometholone.Approved, Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Fluorometholone.Approved, Vet Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Fluorometholone.Approved
MefloquineThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Mefloquine.Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Fluorometholone.Approved, Vet Approved
MemantineThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Memantine.Approved, Investigational
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Fluorometholone.Approved
MesteroloneFluorometholone may increase the fluid retaining activities of Mesterolone.Experimental
MestranolThe serum concentration of Fluorometholone can be increased when it is combined with Mestranol.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Fluorometholone.Investigational, Withdrawn
MethallenestrilThe serum concentration of Fluorometholone can be increased when it is combined with Methallenestril.Experimental
Methanesulfonyl FluorideThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Methanesulfonyl Fluoride.Investigational
MethyclothiazideFluorometholone may increase the hypokalemic activities of Methyclothiazide.Approved
Methyl salicylateThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Fluorometholone.Approved, Vet Approved
MethyltestosteroneFluorometholone may increase the fluid retaining activities of Methyltestosterone.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Metoclopramide.Approved, Investigational
MetolazoneFluorometholone may increase the hypokalemic activities of Metolazone.Approved
MifepristoneThe serum concentration of Fluorometholone can be increased when it is combined with Mifepristone.Approved, Investigational
MinaprineThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Minaprine.Approved
MitotaneThe serum concentration of Fluorometholone can be decreased when it is combined with Mitotane.Approved
MivacuriumMivacurium may increase the adverse neuromuscular activities of Fluorometholone.Approved
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Fluorometholone.Investigational
MofebutazoneThe risk or severity of adverse effects can be increased when Mofebutazone is combined with Fluorometholone.Experimental
MoxestrolThe serum concentration of Fluorometholone can be increased when it is combined with Moxestrol.Experimental
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Fluorometholone.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Fluorometholone.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Nabumetone.Approved
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Fluorometholone.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Fluorometholone.Approved
Nalidixic AcidThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Nalidixic Acid.Approved, Investigational
NandroloneFluorometholone may increase the fluid retaining activities of Nandrolone.Experimental, Investigational
Nandrolone decanoateFluorometholone may increase the fluid retaining activities of Nandrolone decanoate.Approved, Illicit
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Fluorometholone.Approved, Vet Approved
NefazodoneThe metabolism of Fluorometholone can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Fluorometholone can be decreased when combined with Nelfinavir.Approved
NemonoxacinThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Nemonoxacin.Investigational
NeostigmineThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Neostigmine.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Fluorometholone.Approved
NetupitantThe serum concentration of Fluorometholone can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Fluorometholone can be increased when combined with Nevirapine.Approved
NicorandilThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Nicorandil.Approved, Investigational
NifenazoneThe risk or severity of adverse effects can be increased when Nifenazone is combined with Fluorometholone.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Fluorometholone.Approved
NilotinibThe metabolism of Fluorometholone can be decreased when combined with Nilotinib.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Fluorometholone.Approved, Investigational, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Fluorometholone.Investigational
NorfloxacinThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Norfloxacin.Approved
OlaparibThe metabolism of Fluorometholone can be decreased when combined with Olaparib.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Fluorometholone.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Fluorometholone.Approved
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Fluorometholone.Vet Approved
OsimertinibThe serum concentration of Fluorometholone can be increased when it is combined with Osimertinib.Approved
OxandroloneFluorometholone may increase the fluid retaining activities of Oxandrolone.Approved, Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Fluorometholone.Approved
Oxolinic acidThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Oxolinic acid.Experimental
OxymetholoneFluorometholone may increase the fluid retaining activities of Oxymetholone.Approved, Illicit
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Fluorometholone.Approved, Withdrawn
PalbociclibThe serum concentration of Fluorometholone can be increased when it is combined with Palbociclib.Approved
ParaoxonThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Paraoxon.Experimental
ParecoxibThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Parecoxib.Approved
ParthenolideThe risk or severity of adverse effects can be increased when Parthenolide is combined with Fluorometholone.Investigational
PazufloxacinThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Pazufloxacin.Investigational
PefloxacinThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Pefloxacin.Approved
PentobarbitalThe metabolism of Fluorometholone can be increased when combined with Pentobarbital.Approved, Vet Approved
PhenobarbitalThe metabolism of Fluorometholone can be increased when combined with Phenobarbital.Approved
Phenylacetic acidThe therapeutic efficacy of Phenylacetic acid can be decreased when used in combination with Fluorometholone.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Fluorometholone.Approved, Vet Approved
Phenylbutyric acidThe therapeutic efficacy of Phenylbutyric acid can be decreased when used in combination with Fluorometholone.Approved, Investigational
PhenytoinThe metabolism of Fluorometholone can be increased when combined with Phenytoin.Approved, Vet Approved
PhysostigmineThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Physostigmine.Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Fluorometholone.Approved, Investigational
Pipemidic acidThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Pipemidic acid.Experimental
PiretanideFluorometholone may increase the hypokalemic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Fluorometholone.Approved, Investigational
Piromidic acidThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Fluorometholone.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Pirprofen is combined with Fluorometholone.Experimental
Polyestradiol phosphateThe serum concentration of Fluorometholone can be increased when it is combined with Polyestradiol phosphate.Approved
PolythiazideFluorometholone may increase the hypokalemic activities of Polythiazide.Approved
PosaconazoleThe metabolism of Fluorometholone can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PranoprofenThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Fluorometholone.Experimental, Investigational
PrimidoneThe metabolism of Fluorometholone can be increased when combined with Primidone.Approved, Vet Approved
ProglumetacinThe risk or severity of adverse effects can be increased when Proglumetacin is combined with Fluorometholone.Experimental
PromestrieneThe serum concentration of Fluorometholone can be increased when it is combined with Promestriene.Investigational
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Fluorometholone.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Propyphenazone is combined with Fluorometholone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Proquazone is combined with Fluorometholone.Experimental
PrulifloxacinThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Fluorometholone.Investigational
PyridostigmineThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Pyridostigmine.Approved
QuinestrolThe serum concentration of Fluorometholone can be increased when it is combined with Quinestrol.Approved
QuinethazoneFluorometholone may increase the hypokalemic activities of Quinethazone.Approved
Rabies virus inactivated antigen, AThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Rabies virus inactivated antigen, A.Approved
RanolazineThe metabolism of Fluorometholone can be decreased when combined with Ranolazine.Approved, Investigational
RapacuroniumRapacuronium may increase the adverse neuromuscular activities of Fluorometholone.Withdrawn
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Fluorometholone.Approved, Experimental, Investigational
RifabutinThe metabolism of Fluorometholone can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Fluorometholone can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Fluorometholone can be increased when combined with Rifapentine.Approved
RilpivirineThe serum concentration of Rilpivirine can be decreased when it is combined with Fluorometholone.Approved
RindopepimutThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Rindopepimut.Investigational
RivastigmineThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Rivastigmine.Approved, Investigational
RofecoxibThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Rofecoxib.Investigational, Withdrawn
RosoxacinThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Rosoxacin.Approved, Investigational
Rotavirus VaccineThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Rotavirus Vaccine.Approved
Rubella virus vaccineThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Rubella virus vaccine.Approved
RufloxacinThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Rufloxacin.Experimental
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Fluorometholone.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Fluorometholone.Approved, Vet Approved
Salmonella typhi ty21a live antigenThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Salmonella typhi ty21a live antigen.Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Fluorometholone.Approved
SaquinavirThe metabolism of Fluorometholone can be decreased when combined with Saquinavir.Approved, Investigational
SaxagliptinThe serum concentration of Saxagliptin can be decreased when it is combined with Fluorometholone.Approved
SecoisolariciresinolThe serum concentration of Fluorometholone can be increased when it is combined with Secoisolariciresinol.Investigational
SemapimodThe risk or severity of adverse effects can be increased when Semapimod is combined with Fluorometholone.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Fluorometholone.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Fluorometholone.Investigational
SildenafilThe metabolism of Fluorometholone can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Fluorometholone can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Fluorometholone can be increased when it is combined with Simeprevir.Approved
SitafloxacinThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Sitafloxacin.Experimental, Investigational
Sodium bicarbonateThe bioavailability of Fluorometholone can be decreased when combined with Sodium bicarbonate.Approved
SparfloxacinThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Sparfloxacin.Approved, Investigational
SRP 299The risk or severity of adverse effects can be increased when Fluorometholone is combined with SRP 299.Investigational
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Fluorometholone.Investigational
St. John's WortThe serum concentration of Fluorometholone can be decreased when it is combined with St. John's Wort.Investigational, Nutraceutical
StanozololFluorometholone may increase the fluid retaining activities of Stanozolol.Approved, Vet Approved
StiripentolThe serum concentration of Fluorometholone can be increased when it is combined with Stiripentol.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Fluorometholone.Approved
SulfisoxazoleThe metabolism of Fluorometholone can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Fluorometholone.Approved
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Fluorometholone.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Suxibuzone is combined with Fluorometholone.Experimental
Synthetic Conjugated Estrogens, AThe serum concentration of Fluorometholone can be increased when it is combined with Synthetic Conjugated Estrogens, A.Approved
Synthetic Conjugated Estrogens, BThe serum concentration of Fluorometholone can be increased when it is combined with Synthetic Conjugated Estrogens, B.Approved
TacrineThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Tacrine.Investigational, Withdrawn
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Fluorometholone.Investigational
TecemotideThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Tecemotide.Investigational
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Fluorometholone.Approved, Withdrawn
TelithromycinThe metabolism of Fluorometholone can be decreased when combined with Telithromycin.Approved
TemafloxacinThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Temafloxacin.Withdrawn
TenidapThe risk or severity of adverse effects can be increased when Tenidap is combined with Fluorometholone.Experimental
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Fluorometholone.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Fluorometholone.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Fluorometholone.Approved
TestosteroneFluorometholone may increase the fluid retaining activities of Testosterone.Approved, Investigational
Testosterone PropionateFluorometholone may increase the fluid retaining activities of Testosterone Propionate.Approved, Vet Approved
TG4010The risk or severity of adverse effects can be increased when Fluorometholone is combined with TG4010.Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Fluorometholone.Approved
TiboloneThe serum concentration of Fluorometholone can be increased when it is combined with Tibolone.Approved, Investigational
TiclopidineThe metabolism of Fluorometholone can be decreased when combined with Ticlopidine.Approved
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Fluorometholone.Investigational
TocilizumabThe serum concentration of Fluorometholone can be decreased when it is combined with Tocilizumab.Approved
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Fluorometholone.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Fluorometholone.Approved
TorasemideFluorometholone may increase the hypokalemic activities of Torasemide.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Fluorometholone.Approved, Investigational
TribenosideThe risk or severity of adverse effects can be increased when Tribenoside is combined with Fluorometholone.Experimental
TrichlorfonThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Trichlorfon.Vet Approved
TrichlormethiazideFluorometholone may increase the hypokalemic activities of Trichlormethiazide.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Triptolide is combined with Fluorometholone.Investigational
Trolamine salicylateThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Fluorometholone.Approved
TromethamineThe bioavailability of Fluorometholone can be decreased when combined with Tromethamine.Approved
TrovafloxacinThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Trovafloxacin.Approved, Investigational, Withdrawn
TubocurarineThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Tubocurarine.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Valdecoxib.Investigational, Withdrawn
Varicella Zoster Vaccine (Live/Attenuated)The risk or severity of adverse effects can be increased when Fluorometholone is combined with Zoster vaccine.Approved
VenlafaxineThe metabolism of Fluorometholone can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Fluorometholone can be decreased when combined with Verapamil.Approved
VoriconazoleThe metabolism of Fluorometholone can be decreased when combined with Voriconazole.Approved, Investigational
WarfarinFluorometholone may increase the anticoagulant activities of Warfarin.Approved
Yellow fever vaccineThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Yellow fever vaccine.Approved
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Fluorometholone.Approved, Investigational
ZeranolThe serum concentration of Fluorometholone can be increased when it is combined with Zeranol.Vet Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Fluorometholone.Approved, Investigational, Withdrawn
ZiprasidoneThe metabolism of Fluorometholone can be decreased when combined with Ziprasidone.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Fluorometholone.Withdrawn
Food Interactions
Not Available

References

Synthesis Reference

Fried, J.; U.S. Patent 2,852,51 September 16,1958; assigned to Olin Mathieson Chemical Corporation. 
Lincoln, F.H. Jr., Schneider, W.P. and Spero, G.B.; US. Patent 2,867,637; January 6, 1959; assigned to The Upjohn Company
. Lincoln, F.H. Jr., Schneider, W.P. and Spero, G.B.; U.S. Patent 2,867,638; January 6, 1959; assigned to The Upjohn Company. 
Magerlein, B.J., Kagan, F. and Schlagel, C.A.; U.S. Patent 3,038,914; June 12, 1962; assigned to The Upjohn Company.

General References
Not Available
External Links
Human Metabolome Database
HMDB14469
KEGG Drug
D01367
PubChem Compound
9878
PubChem Substance
46505984
ChemSpider
9494
ChEBI
31625
ChEMBL
CHEMBL1200600
Therapeutic Targets Database
DAP001047
PharmGKB
PA164781355
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Fluorometholone
ATC Codes
S01BA07 — FluorometholoneD10AA01 — FluorometholoneD07XB04 — FluorometholoneC05AA06 — FluorometholoneS01CB05 — FluorometholoneD07AB06 — FluorometholoneS01BB03 — Fluorometholone and mydriaticsS01CA07 — Fluorometholone and antiinfectivesD07CB03 — Fluorometholone and antibiotics
AHFS Codes
  • 52:08.08 — Corticosteroids
FDA label
Download (64.7 KB)
MSDS
Download (72 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedPreventionBullous Keratopathy / Fuchs' Dystrophy1
2WithdrawnTreatmentLacrimation increased1
2, 3RecruitingPreventionCorneal Opacity1
3CompletedPreventionFibrosis / Glaucoma / Intraocular Pressure / Trabeculectomy1
3CompletedTreatmentEye Dryness1
4CompletedTreatmentIntraocular Pressure1
4Not Yet RecruitingTreatmentMust be PRK Candidate1
Not AvailableCompletedTreatmentBilamellar Tarsal Rotation / Trachoma / Trichiasis1
Not AvailableCompletedTreatmentModerate to Severe Dry Eye Syndrome1
Not AvailableCompletedTreatmentPterygium of the Conjunctiva and Cornea1
Not AvailableRecruitingNot AvailableDegeneration / Ectasia / Keratoconus2
Not AvailableUnknown StatusTreatmentEye Dryness1
Not AvailableWithdrawnTreatmentDescemet's Stripping Endothelial Keratoplasty / Endothelial Dystrophy / Posterior Lamellar Keratoplasty / Secondary Bullous Keratopathy1

Pharmacoeconomics

Manufacturers
  • Pharmacia and upjohn co
  • Allergan pharmaceutical
  • Novartis pharmaceuticals corp
  • Alcon laboratories inc
Packagers
Dosage forms
FormRouteStrength
Suspension / dropsOphthalmic1 mg/mL
Solution / dropsOphthalmic1 mg/mL
OintmentOphthalmic1 mg/g
Solution / dropsOphthalmic0.1 %
Suspension / dropsOphthalmic2.5 mg/mL
SuspensionOphthalmic0.25 %
SuspensionOphthalmic
SuspensionOphthalmic0.1 %
Prices
Unit descriptionCostUnit
FML Liquifilm 0.1% Suspension 15ml Bottle82.16USD bottle
FML Forte 0.25% Suspension 15ml Bottle60.98USD bottle
FML Liquifilm 0.1% Suspension 10ml Bottle60.17USD bottle
Flarex 0.1% Suspension 10ml Bottle50.7USD bottle
FML Forte 0.25% Suspension 10ml Bottle48.58USD bottle
Flarex 0.1% Suspension 5ml Bottle42.82USD bottle
FML Liquifilm 0.1% Suspension 5ml Bottle41.65USD bottle
FML-S Liquifilm 0.1-10% Suspension 10ml Bottle35.99USD bottle
Fluor-Op 0.1% Suspension 15ml Bottle30.99USD bottle
FML Forte 0.25% Suspension 5ml Bottle30.07USD bottle
Fluor-Op 0.1% Suspension 10ml Bottle25.99USD bottle
Fluor-Op 0.1% Suspension 5ml Bottle17.99USD bottle
Flarex 0.1% eye drops8.11USD ml
Fml liquifilm 0.1% eye drop6.27USD ml
Fml forte 0.25% eye drops5.09USD ml
Fluorometholone 0.1% drops3.25USD ml
Fml Forte 0.25 % Suspension2.96USD ml
Flarex 0.1 % Suspension1.96USD ml
Pms-Fluorometholone 0.1 % Suspension1.73USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)292-303Fried, J.; U.S. Patent 2,852,51 September 16,1958; assigned to Olin Mathieson Chemical Corporation. 
Lincoln, F.H. Jr., Schneider, W.P. and Spero, G.B.; US. Patent 2,867,637; January 6, 1959; assigned to The Upjohn Company
. Lincoln, F.H. Jr., Schneider, W.P. and Spero, G.B.; U.S. Patent 2,867,638; January 6, 1959; assigned to The Upjohn Company. 
Magerlein, B.J., Kagan, F. and Schlagel, C.A.; U.S. Patent 3,038,914; June 12, 1962; assigned to The Upjohn Company.
water solubility30 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP2.00HANSCH,C ET AL. (1995)
logS-4.1ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.0166 mg/mLALOGPS
logP2.34ALOGPS
logP2.42ChemAxon
logS-4.4ALOGPS
pKa (Strongest Acidic)12.65ChemAxon
pKa (Strongest Basic)-3.4ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area74.6 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity100.87 m3·mol-1ChemAxon
Polarizability40.05 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9956
Blood Brain Barrier+0.9716
Caco-2 permeable+0.8169
P-glycoprotein substrateSubstrate0.7834
P-glycoprotein inhibitor INon-inhibitor0.6791
P-glycoprotein inhibitor IINon-inhibitor0.8382
Renal organic cation transporterNon-inhibitor0.8397
CYP450 2C9 substrateNon-substrate0.8762
CYP450 2D6 substrateNon-substrate0.907
CYP450 3A4 substrateSubstrate0.7663
CYP450 1A2 substrateNon-inhibitor0.9149
CYP450 2C9 inhibitorNon-inhibitor0.8345
CYP450 2D6 inhibitorNon-inhibitor0.9232
CYP450 2C19 inhibitorNon-inhibitor0.9285
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9452
Ames testNon AMES toxic0.9025
CarcinogenicityNon-carcinogens0.9404
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.3393 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9694
hERG inhibition (predictor II)Non-inhibitor0.5956
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0079-2960000000-57c1831d283834b32701

Taxonomy

Description
This compound belongs to the class of organic compounds known as gluco/mineralocorticoids, progestogins and derivatives. These are steroids with a structure based on a hydroxylated prostane moiety.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Steroids and steroid derivatives
Sub Class
Pregnane steroids
Direct Parent
Gluco/mineralocorticoids, progestogins and derivatives
Alternative Parents
20-oxosteroids / 11-beta-hydroxysteroids / 17-hydroxysteroids / Halogenated steroids / 3-oxo delta-1,4-steroids / Delta-1,4-steroids / Tertiary alcohols / Alpha-hydroxy ketones / Secondary alcohols / Fluorohydrins
show 6 more
Substituents
Progestogin-skeleton / 20-oxosteroid / 3-oxo-delta-1,4-steroid / 3-oxosteroid / 17-hydroxysteroid / 11-hydroxysteroid / 11-beta-hydroxysteroid / Oxosteroid / 9-halo-steroid / Halo-steroid
show 21 more
Molecular Framework
Aliphatic homopolycyclic compounds
External Descriptors
11beta-hydroxy steroid, 17alpha-hydroxy steroid, glucocorticoid, 20-oxo steroid, fluorinated steroid, 3-oxo-Delta(1),Delta(4)-steroid (CHEBI:31625)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Zinc ion binding
Specific Function
Receptor for glucocorticoids (GC). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modula...
Gene Name
NR3C1
Uniprot ID
P04150
Uniprot Name
Glucocorticoid receptor
Molecular Weight
85658.57 Da
References
  1. Samudre SS, Lattanzio FA Jr, Williams PB, Sheppard JD Jr: Comparison of topical steroids for acute anterior uveitis. J Ocul Pharmacol Ther. 2004 Dec;20(6):533-47. [PubMed:15684812]
  2. Grossman R, Yehuda R, Golier J, McEwen B, Harvey P, Maria NS: Cognitive effects of intravenous hydrocortisone in subjects with PTSD and healthy control subjects. Ann N Y Acad Sci. 2006 Jul;1071:410-21. [PubMed:16891588]
  3. Rautanen A, Eriksson JG, Kere J, Andersson S, Osmond C, Tienari P, Sairanen H, Barker DJ, Phillips DI, Forsen T, Kajantie E: Associations of body size at birth with late-life cortisol concentrations and glucose tolerance are modified by haplotypes of the glucocorticoid receptor gene. J Clin Endocrinol Metab. 2006 Nov;91(11):4544-51. Epub 2006 Aug 8. [PubMed:16895953]
  4. Hammer F, Stewart PM: Cortisol metabolism in hypertension. Best Pract Res Clin Endocrinol Metab. 2006 Sep;20(3):337-53. [PubMed:16980198]
  5. Shaw JR, Gabor K, Hand E, Lankowski A, Durant L, Thibodeau R, Stanton CR, Barnaby R, Coutermarsh B, Karlson KH, Sato JD, Hamilton JW, Stanton BA: Role of glucocorticoid receptor in acclimation of killifish (Fundulus heteroclitus) to seawater and effects of arsenic. Am J Physiol Regul Integr Comp Physiol. 2007 Feb;292(2):R1052-60. Epub 2006 Oct 12. [PubMed:17038445]
  6. Sher L: Combined dexamethasone suppression-corticotropin-releasing hormone stimulation test in studies of depression, alcoholism, and suicidal behavior. ScientificWorldJournal. 2006 Oct 31;6:1398-404. [PubMed:17086345]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inducer
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. El-Sankary W, Bombail V, Gibson GG, Plant N: Glucocorticoid-mediated induction of CYP3A4 is decreased by disruption of a protein: DNA interaction distinct from the pregnane X receptor response element. Drug Metab Dispos. 2002 Sep;30(9):1029-34. [PubMed:12167569]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Steroid binding
Specific Function
Major transport protein for glucocorticoids and progestins in the blood of almost all vertebrate species.
Gene Name
SERPINA6
Uniprot ID
P08185
Uniprot Name
Corticosteroid-binding globulin
Molecular Weight
45140.49 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]

Drug created on June 13, 2005 07:24 / Updated on December 10, 2017 17:18